Thursday, November 07, 2019 11:54:59 AM
CASI Pharmaceuticals Enters Exclusive China Distribution License Agreement For Octreotide Long Acting Injectable (LAI) Microsphere For Neuroendocrine Cancers And Acromegaly
ROCKVILLE, Md. and BEIJING, Nov. 7, 2019 - CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, announces an exclusive distribution agreement with Pharmathen Global BV for the development and distribution of octreotide long acting injectable (LAI) microsphere in China. Octreotide LAI formulations are considered a standard of care for the treatment of acromegaly and for the control of symptoms associated with certain neuroendocrine tumors. Pharmathen has received regulatory approvals in various European countries. CASI will be responsible for the development, import drug registration and product approval in China and has a long-term exclusive distribution right for the China market after product launch.
Wei-Wu He, Ph.D., CASI's Chairman and Chief Executive Officer stated, "Octreotide LAI is an asset that we feel enhances and adds value to our growing portfolio of oncology products. Based on historical data, we are confident in the sales projections for octreotide LAI in China as this market has experienced continued growth over the last several years. We believe octreotide LAI will add significant value to patients with neuroendocrine tumors in China which are likely underreported and potentially mistreated. With improvements in diagnostic testing and clinical detection, the number of neuroendocrine tumors diagnosed and treated in China is expected to increase."
About Octreotide
Octreotide is a synthetic peptide which potently mimics the inhibitory activity of the natural hormone somatostatin. Octreotide LAI microsphere is a slow release formulation of octreotide which reduces the need for frequent physician visits and administration, while maintaining the clinical and pharmacological characteristics of the immediate-release formulation of octreotide.
US prescribing and indication details for Octreotide and Octreotide LAI can be found at https://www.fda.gov/
Recent CASI News
- CASI PHARMACEUTICALS REPORTS DEVELOPMENT RELATING TO ITS DISPUTES WITH JUVENTAS • PR Newswire (US) • 04/08/2024 09:00:00 PM
- CASI PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2023 BUSINESS AND FINANCIAL RESULTS • PR Newswire (US) • 03/28/2024 11:00:00 AM
- CASI Pharmaceuticals Report Positive Interim Phase 1 Data For BI-1206 In The Treatment Of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma In China • PR Newswire (US) • 03/05/2024 12:00:00 PM
- CASI PHARMACEUTICALS ANNOUNCES FIRST DOSING OF FOLOTYN® IN CHINA • PR Newswire (US) • 02/16/2024 12:00:00 PM
- CASI PHARMACEUTICALS ANNOUNCES THIRD QUARTER 2023 BUSINESS AND FINANCIAL UPDATES • PR Newswire (US) • 11/14/2023 12:00:00 PM
- CASI PHARMACEUTICALS ANNOUNCES MARKET APPROVAL OF CNCT19 BY CHINA NMPA • PR Newswire (US) • 11/08/2023 12:00:00 PM
- CASI PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2023 BUSINESS AND FINANCIAL UPDATES • PR Newswire (US) • 08/11/2023 11:00:00 AM
- Mundipharma International Corporation Limited, Mundipharma Medical Company, and Acrotech Biopharma Inc. Enter Agreement to Transfer License of FOLOTYN® (Pralatrexate) in China to CASI Pharmaceuticals • PR Newswire (US) • 08/01/2023 11:00:00 AM
- CASI Pharmaceuticals Acquires Global Intellectual Property Rights to Cleave Therapeutics' VCP/P97 Inhibitor CB-5339 • PR Newswire (US) • 07/20/2023 12:00:00 PM
- CASI PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2023 FINANCIAL RESULTS • PR Newswire (US) • 05/17/2023 11:35:00 AM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM